Skip to main content
. 2023 May 15;17(6):950–963. doi: 10.1002/1878-0261.13446

Fig. 3.

Fig. 3

Schematic overview of EML4‐ALK resistance mechanisms. EML4‐ALK variants generate proteins of different sizes that form cellular compartments. This drives cancer signalling and promotes cancer cell survival pathways that can be blocked with ALK‐TKIs. Resistance pathways can be on‐target and diminish the efficacy of ALK‐TKIs; or off‐target, and bypass the requirement for ALK activity altogether.